Novo Nordisk Clears Two EU Hurdles as Investors Wait for Monday's Verdict
Published on 09/18/2026 at 16:40 | Editorial boerse-global.de
European regulators handed Novo Nordisk a pair of wins on Friday, but the Danish drugmaker's shares barely budged — a sign that the market's attention has already shifted to next week's capital markets day in London.
The company's stock traded at EUR 37.41 in Frankfurt, down 0.9% on the day, even after the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency backed two separate products. The muted reaction underscores how much ground Novo has to recover: the shares are off 15% year-to-date and 29% over twelve months, and sit 32% below their 52-week high of EUR 54.86 reached at the end of January.
A weekly growth hormone and a first-in-class hemophilia option
The panel recommended Sogroya (somapacitan) for once-weekly use in children with idiopathic short stature and persistent growth failure, a condition affecting as many as 3% of children worldwide. In the Phase 3 REAL8 trial, the therapy proved non-inferior to daily growth hormone treatment after 52 weeks. If the European Commission gives its blessing, Sogroya would become the first and only weekly growth hormone therapy approved for this indication in Europe. It is already cleared in the EU for adults with growth hormone deficiency since 2021 and for children aged three and older since 2023; the Commission is expected to rule on all three pediatric indications before the year is out.
In parallel, the committee threw its weight behind Frehemgo (denecimig) for routine prophylaxis in hemophilia A in adults and children, regardless of whether factor VIII inhibitors are present. The pivotal FRONTIER-2 study showed a significantly reduced annual bleeding rate compared with prior prophylaxis. According to Novo, denecimig would be the first factor VIIIa-mimetic agent to offer patients monthly, biweekly or weekly dosing through prefilled injection pens — a flexibility that could set it apart from existing therapies.
CEO Mike Doustdar called the drug a differentiated option that reduces the treatment burden for patients. EU approval is seen as possible within weeks, with a launch in the first markets before year-end and a broader rollout planned for 2027. Analysts project peak annual sales of roughly USD 2 billion.
Should investors sell immediately? Or is it worth buying Novo Nordisk?
Monday looms larger than Brussels
Neither endorsement, however, addresses the core pressure on Novo. Analysts and major shareholders want hard financial targets and greater pipeline clarity at the capital markets day on Monday in London, against the backdrop of an approaching patent cliff and a string of disappointing trial results. Doustdar and CFO Karsten Munk Knudsen will face investors demanding concrete answers.
The company has been in the midst of a broader reset. On Monday it shortened its everyday name to "Novo" and unveiled a new culture concept as part of a strategic reboot aimed at regaining lost ground in the obesity market. Doustdar told Reuters the company must rethink its obesity strategy, and on Tuesday he urged staff to sharpen their customer focus.
Pipeline diversification has meanwhile hit obstacles. In early September, Novo halted two further studies of its experimental cardiovascular drug ziltivekimab, another setback in efforts to broaden beyond obesity and diabetes treatments. Against that backdrop, the Frehemgo recommendation carries extra weight as a counterbalance.
There have been bright spots in the core business too. Novo released initial Phase 3 data from the STEP-Young study of weekly semaglutide combined with calorie reduction and increased exercise in 165 children aged 6 to under 12 with obesity. According to Reuters, 40.4% of treated children — assuming full adherence — were no longer classified as obese after 68 weeks.
AI deals and a Milan data drop
Beyond the regulatory filings, Novo is pushing deeper into artificial intelligence. The group announced a partnership with Anthropic to integrate its Claude Science software into research and development processes, following earlier collaboration with OpenAI. It also struck a deal with Orbis Medicines worth up to USD 1.4 billion in milestone payments for orally available compounds targeting cardiometabolic disease.
The stock remains well below its 50-day moving average of EUR 40.73, a signal that the medium-term downtrend has yet to break. Attention now turns to September 21, when Novo holds its capital markets day in London, and then to September 28 through October 2, when the company participates in the annual meeting of the European Association for the Study of Diabetes in Milan — two appointments that should shed further light on the strategic overhaul.
Ad
Novo Nordisk Stock: New Analysis - 18 September
Fresh Novo Nordisk information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
